november AG
november AG english
november AG continues concentration
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
november AG continues concentration
Erlangen, October 15th, 2002. In order to further increase efficiency of its
research and development efforts, november AG will concentrate solely on its
projects identif technologies (product security and brand protection), lab-on-a-
strip (nucleid acid testing), and its immunotherapeutic approaches to can-cer
therapy.
The development of the Biological Labeling of livestock as part of meat-quality
programs is almost ready for the market. Upon conclusion of a study jointly
conducted together with an internationally leading manufacturer of veterinary
vaccines, the project “Biological Labeling” is completed with regard to in-house
development activities.
november AG’s molecular therapy division will focus its therapeutic R&D
activities solely on immunotherapeutic approaches to cancer therapy. This way,
november AG promotes the approach, which is the most advanced in its pre-
clinical trials. Strategic options for this field are evaluated at the executive
level, as well. R&D capacities formerly assigned to the development of a drug
delivery system (drug delivery and antigen delivery with synthetic polyoma
capsids) will from now on increase prospects of success for november AG’s
immunotherapy approach.
Focusing all strengths onto its most successful projects identif technologies
(solutions for product security and brand protection), directif (lab-on-a-strip,
nucleid acid testing), and responsif (patient-specific immunotherapy
approaches), will promote and accelerate november AG’s future development.
For further information, please contact
Dr. Peer Nils Schroeder
Public Relations, Investor Relations
Ulrich-Schalk-Str. 3
91056 Erlangen, Germany
Tel.: +49 (0)9131 750 88 868
schroeder@november.de
http://www.november.de
end of ad-hoc-announcement (c)DGAP 15.10.2002
——————————————————————————–
WKN: 676290; ISIN: DE0006762909; Index:
Listed: Neuer Markt Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, München, Hannover und Stuttgart
151411 Okt 02
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found